ORAGENICS, INC. Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent
ORAGENICS, INC. (OGEN) reported Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent of $0 for the 3-month period ending 2017-09-30, per its 10-K filed 2019-03-29.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity · last filed 2019-03-29
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2017-06-30 was $121.00, a 99.99% decline year-over-year.
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2017-03-31 was -$121.00, a 101.09% decline year-over-year.
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2016-12-31 was $9.39K.
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2016 was $1.48M, a 1052.68% increase from fiscal 2015.
- ORAGENICS, INC. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2015 was $128.75K.
| Period end | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 3 month as first filed | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | $0.00 10-K · filed 2019-03-29 | $121.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $9.39K derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-06-30 | $121.00 10-K · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $9.39K derived: sum of 3 quarters · filed 2019-03-29 | $51.95K derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-03-31 | -$121.00 10-K · filed 2019-03-29 | $9.27K derived: sum of 2 quarters · filed 2019-03-29 | $51.83K derived: sum of 3 quarters · filed 2019-03-29 | $1.47M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2016-12-31 | $9.39K 10-K · filed 2018-02-16 | $51.95K derived: sum of 2 quarters · filed 2018-02-16 | $1.47M derived: sum of 3 quarters · filed 2018-02-16 | $1.48M 10-K · filed 2018-02-16 | |
| 2016-09-30 | $42.57K 10-K · filed 2018-02-16 | $1.46M derived: sum of 2 quarters · filed 2018-02-16 | $1.47M 10-Q · filed 2017-10-31 | $1.47M derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-06-30 | $1.42M 10-K · filed 2018-02-16 | $1.43M 10-Q · filed 2017-08-14 | $1.43M derived: sum of 3 quarters · filed 2018-02-16 | $1.47M derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-03-31 | $11.11K 10-K · filed 2018-02-16 | $10.94K derived: sum of 2 quarters · filed 2018-02-16 | $47.36K derived: sum of 3 quarters · filed 2018-02-16 | $61.29K derived: sum of 4 quarters · filed 2018-02-16 | |
| 2015-12-31 | -$174.00 10-K · filed 2017-02-27 | $36.24K derived: sum of 2 quarters · filed 2017-02-27 | $50.17K derived: sum of 3 quarters · filed 2017-02-27 | $128.75K 10-K · filed 2017-02-27 | |
| 2015-09-30 | $36.42K 10-K · filed 2017-02-27 | $36.42K 10-Q · filed 2016-11-14 | $50.35K derived: sum of 2 quarters · filed 2017-02-27 | $128.92K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $13.93K 10-K · filed 2017-02-27 | $92.50K 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | $78.57K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |